Xetra
27.01.26 | 17:35
145,20 Euro
0,00 % 0,00
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 143,50 | 145,50 | 08:53 | |
| 143,50 | 145,50 | 08:47 |
► 28.01.: |
10:00 |
11:00 |
12:00 |
12:55 |
14:00 |
15:00 |
16:00 |
17:00 |
17:30
► 27.01.: | | | | | | | | |
► Aktueller BIOGEN Börsenkurs + Xetra-Orderbuch
► 27.01.: | | | | | | | | |
► Aktueller BIOGEN Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 285,00 | 10 | |||
| 266,00 | 40 | |||
| 244,00 | 35 | |||
| 222,00 | 50 | |||
| 175,00 | 24 | |||
| 145,70 | 84 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/idp.htm [/URL] | ||||
| 84 | 144,00 | |||
| 40 | 1,234 | |||
| 1.063 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.187 | 0,205 | 243 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:05:28 | 145,05 | 23 |
| 16:50:34 | 145,05 | 3 |
| 15:37:41 | 146,50 | 75 |
| 15:37:41 | 146,50 | 45 |
| 14:45:04 | 145,10 | 7 |
| 12:50:35 | 144,40 | 15 |
| 10:02:02 | 144,40 | 73 |
| 10:02:02 | 144,40 | 47 |
| 10:02:02 | 144,35 | 53 |
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Expert Outlook: Biogen Through The Eyes Of 11 Analysts | 3 | Benzinga.com | ||
| BIOGEN Aktie jetzt für 0€ handeln | |||||
| Di | JPMorgan maintains Biogen stock rating at Neutral ahead of 2026 guidance | 5 | Investing.com | ||
| Mo | Eisai and Biogen's subcutaneous Leqembi given FDA Priority Review for early Alzheimer's | 7 | PMLiVE | ||
| Mo | FDA Grants Priority Review To Eisai And Biogen's SBLA For LEQEMBI Subcutaneous Autoinjector | 450 | AFX News | WESTON (dpa-AFX) - Eisai Co., Ltd. (ESALY, ESALF, 4523.T) and Biogen Inc. (BIIB) announced that the U.S. Food and Drug Administration has accepted for review Eisai's Supplemental Biologics License... ► Artikel lesen | |
| Mo | Biogen Inc.: FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review | 318 | GlobeNewswire (Europe) | If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA... ► Artikel lesen |
1 2 3 4 5 Weiter >>
252 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Di | Cytokinetics, Incorporated: Cytokinetics Announces MYQORZO (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms | GlobeNewswire (Europe) | MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics,... ► Artikel lesen | |
| Di | Psyence Group Inc.: Psyence Group's RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana's Shallow Continental Shelf | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / January 27, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that its proposed reverse takeover target, GoldCoast Resource Corp. ("GoldCoast")... ► Artikel lesen | |
| Di | VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in revenues in Q4 | Dow Jones News | DJ VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in revenues in Q4
VALBIOTIS SA
VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in... ► Artikel lesen | |
| 07:10 | Idorsia Pharmaceuticals Ltd: Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America | GlobeNewswire (Europe) | Ad hoc announcement pursuant to Art. 53 LR
Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil
Allschwil, Switzerland - January 28, 2026Idorsia... ► Artikel lesen | |
| 07:00 | Psychodelika-Aktien: Sind Bioxyne, Compass Pathways und Atai "the next big thing"? | Small- & Micro Cap Investment |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOGEN INC finden Sie auf Wallstreet Online.